Cargando…
Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
Autores principales: | Deng, Linglong, Petrek, Hannah, Tu, Mei-Juan, Batra, Neelu, Yu, Ai-Xi, Yu, Ai-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465936/ https://www.ncbi.nlm.nih.gov/pubmed/37655312 http://dx.doi.org/10.1016/j.apsb.2023.07.002 |
Ejemplares similares
-
Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo
por: Deng, Linglong, et al.
Publicado: (2021) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023) -
Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023) -
Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)